Attached files

file filename
10-K - FORM 10-K - PHARMACEUTICAL PRODUCT DEVELOPMENT INCd10k.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex21.htm
EX-10.275 - TOPO MASTER SERVICES AGREEMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10275.htm
EX-10.274 - TOPO DEVELOPMENT AND LICENSE AGREEMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10274.htm
EX-10.273 - MULDELTA MASTER SERVICES AGREEMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10273.htm
EX-10.272 - MULDELTA DEVELOPMENT AND LICENSE AGREEMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10272.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex322.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex312.htm
EX-23.1 - CONSENT OF DELOITTE & TOUCHE LLP - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex231.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex311.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the yearly report of Pharmaceutical Product Development, Inc. (“PPD”) on Form 10-K for the period ended December 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David L. Grange, Chief Executive Officer of PPD, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of PPD as of, and for, the periods presented in the Report.

Date: February 26, 2010

 

/s/ David L. Grange

David L. Grange
Chief Executive Officer